{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:15:34Z","timestamp":1780460134502,"version":"3.54.1"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2014,9,5]],"date-time":"2014-09-05T00:00:00Z","timestamp":1409875200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0106824","type":"journal-article","created":{"date-parts":[[2014,9,5]],"date-time":"2014-09-05T18:58:17Z","timestamp":1409943497000},"page":"e106824","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":24,"title":["Potential Therapeutic Benefit of C1-Esterase Inhibitor in Neuromyelitis Optica Evaluated In Vitro and in an Experimental Rat Model"],"prefix":"10.1371","volume":"9","author":[{"given":"Lukmanee","family":"Tradtrantip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithi","family":"Asavapanumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puay-Wah","family":"Phuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. S.","family":"Verkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,9,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"DM Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/jnnp-2012-302310","article-title":"Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders","volume":"84","author":"A Jacob","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/ncpneuro0764","article-title":"Mechanism of disease: aquaporin-4 antibodies in neuromyelitis optica","volume":"4","author":"S Jarius","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"VA Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrn3468","article-title":"Aquaporin water channels in the nervous system","volume":"14","author":"MC Papadopoulos","year":"2012","journal-title":"Nat Rev Neurosci"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"MC Papadopoulos","year":"2013","journal-title":"Lancet Neurol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jns.2011.08.043","article-title":"Autoimmunity in neuromyelitis optica and opticospinal multiple sclerosis: astrocytopathy as a common denominator in demyelinating disorders","volume":"311","author":"J Kira","year":"2011","journal-title":"J Neurol Sci"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/1756285611398939","article-title":"Current and future treatment approaches for neuromyelitis optica","volume":"4","author":"N Collongues","year":"2011","journal-title":"Ther Adv Neurol Disord"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11910-008-0066-2","article-title":"Neuromyelitis optica: diagnosis, pathogenesis, and treatment","volume":"8","author":"B Cree","year":"2008","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3988\/jcn.2013.9.1.36","article-title":"Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody level","volume":"9","author":"SH Kim","year":"2013","journal-title":"J Clin Neurol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"CF Lucchinetti","year":"2002","journal-title":"Brain"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/brain\/awm047","article-title":"Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis","volume":"130","author":"T Misu","year":"2007","journal-title":"Brain"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/brain\/awl371","article-title":"Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis","volume":"130","author":"SF Roemer","year":"2007","journal-title":"Brain"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jneuroim.2009.07.014","article-title":"Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: an in vitro study","volume":"215","author":"L Sabater","year":"2009","journal-title":"J Neuroimmunol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","article-title":"Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica","volume":"69","author":"SR Hinson","year":"2007","journal-title":"Neurology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1001\/archneurol.2009.188","article-title":"Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells","volume":"66","author":"SR Hinson","year":"2009","journal-title":"Arch Neurol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.21802","article-title":"Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica","volume":"66","author":"JL Bennett","year":"2009","journal-title":"Ann Neurol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/ana.22551","article-title":"Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms","volume":"70","author":"H Zhang","year":"2011","journal-title":"Ann Neurol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","article-title":"Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice","volume":"133","author":"S Saadoun","year":"2010","journal-title":"Brain"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00401-013-1204-8","article-title":"Unique neuromyelitis optica pathology produced in na\u00f2ve rats by intracerebral administration of NMO-IgG","volume":"127","author":"N Asavapanumas","year":"2014","journal-title":"Acta Neuropathol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"SJ Pittock","year":"2013","journal-title":"Lancet Neurol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(09)60001-5","article-title":"Eculizumab for paroxysmal nocturnal haemoglobinuria","volume":"373","author":"C Parker","year":"2009","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00401-013-1128-3","article-title":"C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica","volume":"125","author":"PW Phuan","year":"2013","journal-title":"Acta Neuropathol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0031-6997(24)01437-6","article-title":"C1-esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of disease other than hereditary angioedema","volume":"52","author":"C Caliezi","year":"2000","journal-title":"Pharmacol Rev"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4172\/2329-8790.1000113","article-title":"C1-esterase inhibitor: biological activities and therapeutic applications","volume":"1","author":"E Karnaukhova","year":"2013","journal-title":"J Hematol Thromb Dis"},{"key":"ref26","article-title":"Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica","volume":"1","author":"M Levy","year":"2014","journal-title":"Neurol Neuroimmunol Neutoinflamm"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"13829","DOI":"10.1074\/jbc.M112.344325","article-title":"Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays","volume":"287","author":"PW Phuan","year":"2012","journal-title":"J Biol Chem"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1021\/cr010170+","article-title":"Serpin structure, mechanism, and function","volume":"102","author":"PG Gettins","year":"2002","journal-title":"Chem Rev"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"788","DOI":"10.4049\/jimmunol.123.2.788","article-title":"Active disassembly of the first complement component, C1, by C1 inactivator","volume":"123","author":"RJ Ziccardi","year":"1979","journal-title":"J Immunol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.4049\/jimmunol.148.10.3210","article-title":"Heparin and modified heparin inhibit complement activation in vivo","volume":"148","author":"JM Weiler","year":"1992","journal-title":"J Immunol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"808","DOI":"10.4049\/jimmunol.1000184","article-title":"Cutting edge: C1q binds deoxyribose and heparin sulfate through neighboring sites of its recognition domain","volume":"185","author":"V Garlatti","year":"2010","journal-title":"J Immunol"},{"key":"ref32","first-page":"459","article-title":"The reaction between the complement subcomponent C1q, IgG complexes and polyionic molecules","volume":"34","author":"NC Hughes-Jones","year":"1978","journal-title":"Immunol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.4049\/jimmunol.159.4.1953","article-title":"Potentiation of C1 inhibitor by glycosaminoglycans","volume":"159","author":"WA Wuillemin","year":"1997","journal-title":"J Immunol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"21100","DOI":"10.1074\/jbc.M700841200","article-title":"C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease","volume":"282","author":"L Beinrohr","year":"2007","journal-title":"J Biol Chem"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.expneurol.2014.03.004","article-title":"Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica","volume":"255","author":"J Ratelade","year":"2014","journal-title":"Exper Neurol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"16516","DOI":"10.1074\/jbc.M111.227298","article-title":"Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1\/M23 isoforms and orthogonal arrays","volume":"286","author":"JM Crane","year":"2011","journal-title":"J Biol Chem"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","article-title":"Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy","volume":"70","author":"I Ayzenberg","year":"2013","journal-title":"JAMA Neurol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ana.22657","article-title":"Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica","volume":"71","author":"L Tradtrantip","year":"2012","journal-title":"Ann Neurol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ana.22686","article-title":"Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain","volume":"71","author":"S Saadoun","year":"2012","journal-title":"Ann Neurol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1172\/JCI67554","article-title":"Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica","volume":"123","author":"H Zhang","year":"2013","journal-title":"J Clin Invest"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.molimm.2007.07.008","article-title":"Elucidation of the substrate specificity of the MASP-2 protease of the lectin complement pathway and identification of the enzyme as a major physiological target of the serpin, C1-inhibitor","volume":"45","author":"FK Kerr","year":"2008","journal-title":"Mol Immunol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2147\/TCRM.S3172","article-title":"Treatment of hereditary angioedema with plasma-derived C1 inhibitor","volume":"4","author":"MJ Prematta","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.molmed.2008.12.001","article-title":"C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress","volume":"15","author":"M Cugno","year":"2009","journal-title":"Trend Mol Med"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.molimm.2014.06.003","article-title":"Inhibitors of the classical complement pathway in mouse serum limit the utility of mice as experimental models of neuromyelitis optica","volume":"62","author":"J Ratelade","year":"2014","journal-title":"Mol Immunol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0171-2985(98)80041-7","article-title":"Pathogenetic and clinical aspects of C1 inhibitor deficiency","volume":"199","author":"M Cicardi","year":"1998","journal-title":"Immunobiol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1046\/j.1537-2995.1998.38698326333.x","article-title":"A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema","volume":"38","author":"M Kunschak","year":"1998","journal-title":"Transfusion"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1182\/blood-2012-11-467209","article-title":"C1-esterase inhibitor concentrate rescues erythrocyte from complement-mediated destruction in autoimmune hemolytic anemia","volume":"121","author":"D Wouters","year":"2013","journal-title":"Blood"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.4049\/jimmunol.141.11.3930","article-title":"A mechanism for the spontaneous activation of the first component of complement, C1, and its regulation by C1-inhibitor","volume":"141","author":"AC Bianchino","year":"1988","journal-title":"J Immunol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.molimm.2006.10.003","article-title":"Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement","volume":"44","author":"EW Nielsen","year":"2007","journal-title":"Mol Imunol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"625","DOI":"10.4049\/jimmunol.137.2.625","article-title":"Activator-bound C1 is less susceptible to inactivation by C1 inhibition than is fluid-phase C1","volume":"137","author":"AJ Tenner","year":"1986","journal-title":"J Immunol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0106824","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T13:48:16Z","timestamp":1746366496000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0106824"}},"subtitle":[],"editor":[{"given":"Jun-ichi","family":"Kira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,9,5]]},"references-count":50,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2014,9,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0106824","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,5]]}}}